A Rutgers University study found that GLP-1 medications like Ozempic and Wegovy may reduce violent behavior risk by weakening the link between impulsivity, alcohol use, and violence. The study analyzed data from 7,521 U.S. adults, focusing on 821 GLP-1 users, and suggested these drugs might act similarly to cognitive behavioral therapy. Researchers caution the findings are not causal and call for more research on GLP-1s' impact on behavior and public safety. These drugs, originally for diabetes and obesity, are increasingly used and linked to other health benefits and side effects.
June is proving to be a month for stock pickers focusing on three large-cap companies trading well below their highs but showing signs of recovery. Lululemon is down 46% year-to-date, facing challenges in North America but buoyed by strong internatio...
GLP-1 drugs for weight loss are rapidly expanding worldwide, with Novo Nordisk's Wegovy® pill reaching over three million prescriptions since January 2026 and launching in the UAE and UK. Eli Lilly's investigational drug retatrutide shows significant...
The global GLP-1 receptor agonist market, used primarily for type 2 diabetes and obesity management, is projected to grow from $28.7 billion in 2025 to $95.3 billion by 2035, at a compound annual growth rate of 12.1%. Growth is fueled by rising diabe...
Novo Nordisk has regained investor confidence driven by strong demand for its Wegovy weight loss pill, which is helping stabilize its market share. While the company expects a 7% sales decline in 2024 due to U.S. pricing pressures, its international ...
Novo Nordisk reported a decline in adjusted sales and operating profit for Q1 2026, yet its obesity care segment, particularly the Wegovy pill, showed strong growth and outperformed competitors like Eli Lilly. The company benefits from patent protect...
